Home Tags SORAYA trial
Tag: SORAYA trial
Mirvetuximab Soravtansine Demonstrates Overall Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer
Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.
FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...